896 related articles for article (PubMed ID: 16291412)
1. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference.
Leonardi A; Zafirakis P
Curr Med Res Opin; 2004 Aug; 20(8):1167-73. PubMed ID: 15324519
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
6. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.
Mortemousque B; Bourcier T; Khairallah M; Messaoud R; Brignole-Baudouin F; Renault D; Rebika H; Brémond-Gignac D;
J Fr Ophtalmol; 2014 Jan; 37(1):1-8. PubMed ID: 24388379
[TBL] [Abstract][Full Text] [Related]
7. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
Crampton HJ
Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
Abelson MB; Ferzola NJ; McWhirter CL; Crampton HJ
Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
Spangler DL; Abelson MB; Ober A; Gotnes PJ
Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
[TBL] [Abstract][Full Text] [Related]
12. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.
Shah SR; Nayak A; Ratner P; Roland P; Michael Wall G
Clin Ther; 2009 Jan; 31(1):99-107. PubMed ID: 19243710
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
[TBL] [Abstract][Full Text] [Related]
15. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
[TBL] [Abstract][Full Text] [Related]
16. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis.
Khurana S; Sharma N; Agarwal T; Chawla B; Velpandian T; Tandon R; Titiyal JS
Eye Contact Lens; 2010 Jul; 36(4):210-4. PubMed ID: 20531202
[TBL] [Abstract][Full Text] [Related]
17. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
Lanier BQ; Gross RD; Marks BB; Cockrum PC; Juniper EF
Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
[TBL] [Abstract][Full Text] [Related]
18. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
Abelson MB
Ann Allergy Asthma Immunol; 1998 Sep; 81(3):211-8. PubMed ID: 9759796
[TBL] [Abstract][Full Text] [Related]
20. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
Rosenwasser LJ; O'Brien T; Weyne J
Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]